The Clorox Company (CLX)

Investment Committee Summary

Investment Thesis

At $107 (25 August 2026) Clorox trades on roughly 17x forward earnings for a portfolio the market treats as ex-growth, with a dividend yield high enough to signal doubt about payout durability against net debt of ~$3.3B. The engine's view is more balanced than the headline multiple but it is not constructive. Probability-weighted value is $94.42 and the twelve-month target $94.50, while the blend triangulates to $80.23 — a gap of -25% that leaves the shares trading rich to the anchor set and produces SELL. The anchors themselves disagree sharply: the cash-flow read on a conservative terminal multiple is the lowest in the set, the terminal-growth variant is materially higher, and peer cross-reads higher again. That dispersion is a warning about anchor reliability, not a menu to choose from, and it is why this is a valuation call rather than a contrarian value trade. An operating margin of 14% is respectable but is being defended with price rather than volume. The single most damaging risk is private-label substitution compressing earnings and the multiple together — the structural scenario that puts the target below the 52-week low.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($107) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear has a coherent mechanism. Clorox's core categories — bleach, trash bags, wipes, charcoal — are functionally commoditised; private label matches performance at a visible shelf-price discount, and retailers have every incentive to push it as consumers trade down. Post-inflation pricing rebuilt margin but shed volume, and once the pricing lever is exhausted the arithmetic turns: negative volume, mix erosion and promotional reinvestment push the operating margin well below 14% while revenue contracts outright. With net debt of ~$3.3B and a dividend consuming most of free cash flow, the balance sheet offers no offset and the payout becomes the adjustment variable rather than the support. Earnings and the multiple de-rate together from 17x, which is how the structural target lands below the 52-week low.

Key Debate

Gross Margin explains 55% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 18.4× consensus forward EPS, vs the house DCF terminal 13.0×, and a peer median 23.6×. The house DCF sits 36% below spot, so the market is pricing in more than the house case — roughly 3.0pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily margin-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Private-Label / Brand Erosion' downside ($43.70) to a 'Bull — Defensive Re-Rate' bull case ($150); the probability-weighted blend (PWEV $94.42) is -12% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.7% of revenue; free cash flow net of SBC is $0.36B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Private-Label / Brand Erosion (20%, $43.70). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Consumer / Input Recession (18%, $77.70). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising.
• Base — Pricing-Led Organic Growth (34%, $101). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns.
• Growth — Premium Innovation + EM (20%, $127). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Defensive Re-Rate (8%, $150). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $83.15 and 30% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (55% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 7.5%, 13.0x terminal FCF multiple → $68.85. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $186; the peer-median forward P/E is 23.6x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 124% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 15.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 19.5× (simple median 23.6×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $84.70–$127, centre $104 (-3% vs spot); spot sits at the 53rd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Defensive Re-Rate): $150.

Company Overview & Business Model

The Clorox Company — CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS. The Clorox Company, based in Oakland, California, is an American global manufacturer and marketer of consumer and professional products.

How it makes money.

Edge. Narrow moat — Clorox has a narrow moat from #1/#2 U.S. share in cleaning/bleach, trash bags (Glad), charcoal (Kingsford) and Burt's Bees - strong domestic brands but a smaller, less-international, more-concentrated portfolio than CL/CHD. The falsifiable test is category volume defence post-pandemic normalisation and after the ERP/cyber disruption; if volumes stay ex-growth and net debt caps reinvestment, the ~15x forward multiple is appropriate and should not re-rate toward the ~23x peer level.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2026-06-30 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 102% — cash-backed.

Competitive Moat

Moat sources:

• FACT: #1/#2 U.S. share in cleaning/disinfecting (Clorox bleach/wipes), trash bags (Glad) and charcoal (Kingsford)
• INFERENCE: brand trust in disinfecting (reinforced during the pandemic) supports pricing, though the volume boost has faded
• ABSENCE: limited international scale and a concentrated, mature category set leave less growth runway than CL/CHD
• ABSENCE: $3.3bn net debt constrains the reinvestment/acquisition flywheel that supports peers' moats

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q3): management +0.19 vs analyst floor +0.00 → delta +0.19 (n=27 mgmt / 20 Q&A; 9th pctile across the S&P book, z -1.4).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1292 articles): avg ticker sentiment +0.04 (bullish 16% / bearish 10%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-09-15 (~22d) — ERP/digital-transformation go-live milestone and margin-recovery update (authored)
• 2026-11-03 (~71d) — FQ1 2027 results + gross-margin recovery and dividend coverage (authored)
• 2027-02-01 (~161d) — Portfolio-optimisation / divestiture update (non-core brand pruning) (authored)

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +10.2%.
• Prior-forecast backtest (11 snapshots, 2026-06-26→2026-08-20): directional hit-rate 18%; mean predicted -4.9% vs realised +7.8%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 15 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic sales growth (YoY) < 1% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Operating margin (fully loaded) < 13% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Organic volume contribution to sales growth < -2% while price/mix remains positive (2 consecutive prints). Volume declining while pricing holds is the trade-down signature: consumers substituting to private label rather than deferring purchases. It distinguishes structural share loss from a cyclical demand pause.
• US tracked-channel share in core categories (bleach, trash bags, wipes, charcoal) declining measurable share loss in 2 or more of the 4 largest categories (2 consecutive prints). The structural scenario's mechanism is private-label substitution in functionally commoditised categories. Broad-based share loss, not a single-category wobble, confirms the brand premium is eroding.
• Net debt / EBITDA > 3.0x (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $107; 52-week range $84.70–$127; engine rating SELL; house target $94.50 (-12%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $80.23 (-25% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

50.4/100 (confidence band 37.5–63.2), 21st percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 50.9 → 50.9 → 50.8 → 50.8 → 50.8 → 51.3 → 50.9 → 50.9.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $94.42.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.15, vs QQQ +0.04 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Protective Put. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish/holder — hedge the position; a collar finances the put by capping upside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 38th percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 54th percentile of its own month-end history (decile 6).
• IV term structure is in contango (longer-dated richer, slope +3.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Protective Put was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +3.9pp): 25-DTE 30% · 53-DTE 32% · 235-DTE 34%

No live-chain Protective Put was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: Collar, Put Debit Spread. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 29.8% (moderate regime) · expected move ±6.0% (2026-09-18) · put/call OI 0.91 · ATM Δ 0.63 / Θ -0.07 / ν 0.11. Direction: NEUTRAL (implied return -25.1% to triangulated fair value $80.23).

Covered Call (if held) (Income / neutral) — Short 115 C · 2026-09-18 · premium $0.93 · yield 0.9% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 100 P / Long 90 P · 2026-10-16 · net $1.5 · net entry $98.50 · yield 1.5% · RoR 18.0% · max loss $8.50 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 95 P / Short 120 C · 2027-03-19 · net $1.0 · floor -11.0% · cap +12.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -12% vs spot
• Monte Carlo median implies -22% vs spot
• DCF fair value implies -36% vs spot — but this is terminal-value sensitive (exit-multiple $68.85 vs Gordon $108, 57% apart), so it carries less weight
• Bear case (Structural — Private-Label / Brand Erosion) downside is -59% vs spot
• Net: the valuation anchor itself sits 25.1% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 7.5% · Σ PV(FCF) $3B + PV(terminal) $8B = EV $12B; − net debt $3.3B → equity $8B ÷ diluted shares $0.12B = $68.85/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $108/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 13% vs WACC 7.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $186 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (40.0); Revenue CAGR ±3pp (25.0); Terminal × ±15% (20.0); WACC ±1pp (8.0); Capex intensity ±15% (8.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 7.5%, terminal multiple 13×, FY+5 revenue $8B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.